Gruss & Co’s Health Catalyst HCAT Stock Holding History

Gruss & Co’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,000	Closed	-$188K	–	19
2024 Q1	$188K	Buy	+25,000	New	+$228K	1.04%	20

Other funds holding HCAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Daventry Group New York $133M AUM 32.28% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Gruss & Co's HCAT Position: Q2 2024 in Review

Gruss & Co sold out of Health Catalyst (HCAT) in Q2 2024, closing a stake of 25,000 shares — an estimated $188K sold.

Gruss & Co first reported a position in HCAT in Q1 2024 and held it in 1 quarter. The position peaked at $188K in Q1 2024. 161 funds tracked by Wall St. Rank hold HCAT as of Q2 2024.

Gruss & Co reported no remaining Health Catalyst position as of Q2 2024 after selling out during the quarter.
Gruss & Co sold 25,000 Health Catalyst shares in Q2 2024, an estimated $188K.
Gruss & Co first reported a position in Health Catalyst in Q1 2024 and held it in 1 quarter.
Gruss & Co's Health Catalyst position peaked at $188K in Q1 2024.
161 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2024.

Based on Gruss & Co's 13F filing for Q2 2024, filed 8 Aug 2024.